Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
Oslo, November 28, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that Aitana Peire, Ph.D., has notified the Chair of the Board of Directors that she will resign as a board member due to her recent appointment as Director of Investments at The Johns Hopkins University.
Aitana Peire has held the position as Investment Director of Canica’s Future of Health assets and served as a member of Ultimovacs’ Board of Directors since 2020. Her resignation from the Ultimovacs Board of Directors is effective on the 13th of December 2023. The election for her successor on the Board will take place at the Ordinary Annual Meeting in 2024.
“On behalf of the Board and the whole team at Ultimovacs, we want to thank Aitana for her dedication and impactful contribution during her tenure as a board member. The Company has benefited greatly from her depth of knowledge and invaluable guidance. Her professionalism, global network, and exemplary reputation in investment management and the biotech industry have benefited the Company considerably. As Aitana embarks on a new chapter in her career, we wish her all the best and continued success in her future endeavors,” said Jonas Einarsson, Chair of the Board of Directors of Ultimovacs.
“I’m proud of Ultimovacs’ accomplishments since 2020, and I’m grateful for the opportunity to have served on the Board of Directors and contributed to the Company’s successful development,” says Aitana Peire. “I believe the Company is well-positioned for future accomplishments in the emerging cancer vaccine market and to deliver shareholder value in the years ahead. I look forward to seeing the company continue its progress and deliver on its potential to benefit cancer patients.”
==ENDS==
About Ultimovacs
Ultimovacs is a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines with broad applicability. Ultimovacs’ lead cancer vaccine candidate UV1 is directed against human telomerase (hTERT), an antigen present in 85-90% of cancers in all stages of tumor growth. A broad clinical program, with Phase II trials in five cancer indications enrolling more than 670 patients, aims to demonstrate UV1’s impact in combination with other immunotherapies in multiple cancer types expressing telomerase and where patients have unmet medical needs. UV1 is universal, off-the-shelf, easy to use, and a patented technology owned by Ultimovacs.
In addition, Ultimovacs’ adjuvant platform, based on the proprietary Tetanus-Epitope-Targeting (TET) technology, combines tumor-specific antigens and adjuvant in the same molecule and is in Phase I clinical development.
The Company is listed on the Euronext Oslo Stock Exchange (ULTI.OL).
For further information, please see or contact:
Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA
Email:
Phone: +47 480 96355
This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. Anne Worsøe, Head of Investor Relations at Ultimovacs ASA, published this stock exchange announcement on November 28, 2023, at 07:00 CET.
